[go: up one dir, main page]

MX373713B - Compuestos pirazolopirimidina. - Google Patents

Compuestos pirazolopirimidina.

Info

Publication number
MX373713B
MX373713B MX2016006336A MX2016006336A MX373713B MX 373713 B MX373713 B MX 373713B MX 2016006336 A MX2016006336 A MX 2016006336A MX 2016006336 A MX2016006336 A MX 2016006336A MX 373713 B MX373713 B MX 373713B
Authority
MX
Mexico
Prior art keywords
pyrazolopyrimidine compounds
formula
pyrazolopyrimidine
compounds
pharmaceutically acceptable
Prior art date
Application number
MX2016006336A
Other languages
English (en)
Other versions
MX2016006336A (es
Inventor
Grace Ng
Radoslaw Laufer
Sze-Wan Li
Yong Liu
Narendra Kumar B Patel
Heinz W Pauls
Original Assignee
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Health Network filed Critical Univ Health Network
Publication of MX2016006336A publication Critical patent/MX2016006336A/es
Publication of MX373713B publication Critical patent/MX373713B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Las presentes enseñanzas proveen un compuesto representado por la siguiente fórmula estructural: (ver Fórmula) o una sal farmacéuticamente aceptable del mismo; también se describen composiciones farmacéuticas y métodos de uso de las mismas.
MX2016006336A 2012-11-16 2016-05-13 Compuestos pirazolopirimidina. MX373713B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261727581P 2012-11-16 2012-11-16
US201361808152P 2013-04-03 2013-04-03
PCT/CA2013/000957 WO2014075168A1 (en) 2012-11-16 2013-11-15 Pyrazolopyrimidine compounds
PCT/CA2014/051091 WO2015070349A1 (en) 2012-11-16 2014-11-14 Pyrazolopyrimidine compounds

Publications (2)

Publication Number Publication Date
MX2016006336A MX2016006336A (es) 2016-09-06
MX373713B true MX373713B (es) 2025-03-05

Family

ID=50730425

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006336A MX373713B (es) 2012-11-16 2016-05-13 Compuestos pirazolopirimidina.

Country Status (24)

Country Link
US (9) US9573954B2 (es)
EP (2) EP2920181B1 (es)
JP (1) JP6377068B2 (es)
CN (1) CN105793261B (es)
AU (1) AU2013344716B2 (es)
BR (1) BR112016010080B1 (es)
CA (1) CA2889919C (es)
CY (1) CY1120480T1 (es)
DK (1) DK3068786T3 (es)
ES (1) ES2686097T3 (es)
HR (1) HRP20181041T1 (es)
HU (1) HUE039351T2 (es)
IL (1) IL245187B (es)
LT (1) LT3068786T (es)
ME (1) ME03093B (es)
MX (1) MX373713B (es)
NZ (1) NZ707432A (es)
PL (1) PL3068786T3 (es)
PT (1) PT3068786T (es)
RS (1) RS57481B1 (es)
SG (1) SG11201603102TA (es)
SI (1) SI3068786T1 (es)
TW (1) TWI679201B (es)
WO (2) WO2014075168A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6377068B2 (ja) * 2012-11-16 2018-08-22 ユニバーシティ・ヘルス・ネットワーク ピラゾロピリミジン化合物
EA029372B1 (ru) * 2013-11-15 2018-03-30 Юниверсити Хелс Нетуорк Пиразолопиримидиновые соединения
AU2015315324A1 (en) * 2014-09-08 2017-03-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancer comprising administering a PPAR-gamma agonist
CA2966581A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders
JP6734860B2 (ja) 2014-11-06 2020-08-05 リソソーマル・セラピューティクス・インコーポレイテッドＬｙｓｏｓｏｍａｌ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 置換ピラゾロ［１，５−ａ］ピリミジンおよび医療疾患の治療におけるその使用
WO2016073889A1 (en) 2014-11-06 2016-05-12 Lysosomal Therapeutics Inc. Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders
EP3313842B1 (en) * 2015-06-24 2020-04-15 Curovir Ab Pyrazolo[1,5-a]triazin-4-amine derivatives useful in therapy
EP3440081A4 (en) 2016-04-06 2019-09-18 Lysosomal Therapeutics Inc. PYRROLO [1,2-A] PYRIMIDINYL-CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDER
MX2018012208A (es) 2016-04-06 2019-03-28 Lysosomal Therapeutics Inc Compuestos a base de imidazo [1,5-a] pirimidinil carboxamida y su uso en el tratamiento de trastornos médicos.
CN109311887B (zh) 2016-04-06 2022-09-13 Bial研发投资股份有限公司 吡唑并[1,5-a]嘧啶基甲酰胺化合物以及它们在治疗医学病症中的用途
US11168087B2 (en) 2016-05-05 2021-11-09 Bial—R&D Investments, S.A. Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders
EP3452455A4 (en) 2016-05-05 2019-11-13 Lysosomal Therapeutics Inc. SUBSTITUTED IMDAZO [1,2-] PYRIDINES, SUBSTITUTED IMIDAZO [1,2-] PYRAZINES, RELATED COMPOUNDS AND THEIR USE IN THE TREATMENT OF ILLNESSES
RU2021124795A (ru) 2016-07-18 2021-09-14 Юниверсити Хелс Нетуорк Твердые формы ингибитора ttk
KR102717819B1 (ko) 2017-07-28 2024-10-14 다케다 야쿠힌 고교 가부시키가이샤 Tyk2 억제제 및 이의 용도
WO2019023786A1 (en) * 2017-08-01 2019-02-07 University Health Network COMBINED THERAPIES FOR THE INHIBITION OF TTK PROTEIN KINASE
CA3101035A1 (en) * 2018-05-23 2019-11-28 University Health Network Methods of treating cancers characterized by a high expression level of spindle and kinetochore associated complex subunit 3 (ska3) gene
MX2021004769A (es) 2018-10-30 2021-08-24 Kronos Bio Inc Compuestos, composiciones, y metodos para modular la actividad cdk9.
CN111377925B (zh) * 2018-12-28 2024-03-12 四川科伦博泰生物医药股份有限公司 嘌呤类衍生物、其制备方法及其在医药上的应用
CN112142744A (zh) * 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
TW202146416A (zh) * 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
CN113773324B (zh) * 2021-09-07 2022-07-26 武汉九州钰民医药科技有限公司 抗肿瘤药cfi-402257的合成制备工艺
CN116396298A (zh) * 2023-06-06 2023-07-07 四川维亚本苑生物科技有限公司 CDK Ligand-1的中间体XII及CDK Ligand-1的制备方法

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4021556A (en) * 1972-06-08 1977-05-03 Icn Pharmaceuticals, Inc. Xanthine oxidase inhibitors
JPH04156453A (ja) 1990-10-19 1992-05-28 Konica Corp 新規な写真用カプラー
JPH04156452A (ja) 1990-10-19 1992-05-28 Konica Corp 新規な写真用カプラー
US6060478A (en) 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
US6191131B1 (en) 1997-07-23 2001-02-20 Dupont Pharmaceuticals Company Azolo triazines and pyrimidines
US6124289A (en) 1996-07-24 2000-09-26 Dupont Pharmaceuticals Co. Azolo triazines and pyrimidines
WO2000059907A2 (en) 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolotriazines as crf antagonists
AU7738100A (en) 1999-09-30 2001-04-30 Neurogen Corporation Certain alkylene diamine-substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines
CZ20021089A3 (cs) 1999-09-30 2002-11-13 Neurogen Corporation Aminosustituované pyrazolo[1,5-a]-1,5-pyrimidiny a pyrazolo[1,5-a]-1,3,5-triaziny
US7067520B2 (en) 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
AU2003217712A1 (en) 2002-03-07 2003-09-22 Smithkline Beecham Corporation Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them
US7662826B2 (en) 2002-04-23 2010-02-16 Shionogi & Co., Ltd. Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same
FR2842809A1 (fr) 2002-07-26 2004-01-30 Greenpharma Sas NOUVELLES PYRAZOLO[1,5-a]-1,3,5-TRIAZINES SUBSTITUEES ET LEURS ANALOGUES, COMPOSITIONS PHARMACEUTIQUES LES CONTENANT, UTILISATION A TITRE DE MEDICAMENT ET PROCEDES POUR LEUR PREPARATION
EP1572113B1 (en) 2002-08-26 2017-05-17 Takeda Pharmaceutical Company Limited Calcium receptor modulating compound and use thereof
MXPA05002573A (es) 2002-09-04 2005-09-08 Schering Corp Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina.
NZ539165A (en) 2002-09-04 2008-03-28 Schering Corp Pyrazolopyrimidines as cyclin-dependent kinase inhibitors
US7119200B2 (en) 2002-09-04 2006-10-10 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7605155B2 (en) 2002-09-04 2009-10-20 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
AU2003299651A1 (en) * 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
US7169801B2 (en) 2003-03-17 2007-01-30 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20070179161A1 (en) 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
US7285550B2 (en) 2003-04-09 2007-10-23 Biogen Idec Ma Inc. Triazolotriazines and pyrazolotriazines and methods of making and using the same
ATE418555T1 (de) 2003-04-09 2009-01-15 Biogen Idec Inc A2a-adenosinrezeptorantagonisten
DE602004025504D1 (de) 2003-12-23 2010-03-25 Novartis Ag Bicyclische heterocyclische p-38-kinase-inhibitoren
PE20051128A1 (es) 2004-02-25 2006-01-16 Schering Corp Pirazolotriazinas como inhibidores de quinasa
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
EP1910369A1 (en) 2005-07-29 2008-04-16 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
US7723336B2 (en) 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
CA2627623C (en) 2005-10-06 2014-04-22 Schering Corporation Methods for inhibiting protein kinases
EP1873157A1 (en) 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
CA2667487C (en) 2006-11-06 2017-04-04 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008056176A1 (en) 2006-11-10 2008-05-15 Scottish Biomedical Limited Pyrazolopyrimidines as phosphodiesterase inhibitors
WO2009014620A1 (en) * 2007-07-20 2009-01-29 Merck & Co., Inc. Pyrazolo[1,5-a]pyrimidine derivatives
US20100029657A1 (en) 2008-02-29 2010-02-04 Wyeth Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
GB0908957D0 (en) 2009-05-22 2009-07-01 Ucb Pharma Sa Therapeutic agents
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
US8759359B2 (en) 2009-12-18 2014-06-24 Incyte Corporation Substituted heteroaryl fused derivatives as PI3K inhibitors
EP2525659B1 (en) 2010-01-19 2019-02-27 Merck Sharp & Dohme Corp. PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
WO2011151259A1 (en) 2010-06-01 2011-12-08 Bayer Pharma Aktiengesellschaft Substituted imidazopyrazines
US20120083498A1 (en) 2010-06-17 2012-04-05 Fatah Kashanchi Modulators of Viral Transcription, and Methods and Compositions Therewith
US20120149708A1 (en) 2010-06-17 2012-06-14 George Mason University Modulators of viral transcription, and methods and compositions therewith
PL2585467T3 (pl) 2010-06-24 2016-09-30 PIRAZOLO[1,5-A]PIRYMIDYNY i –TRIAZYNY JAKO ŚRODKI ANTYWIRUSOWE
EP2402337A1 (en) 2010-06-29 2012-01-04 Basf Se Pyrazolopyridine compounds
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
CN103429591A (zh) * 2010-12-17 2013-12-04 拜耳知识产权有限责任公司 在治疗过度增殖性病症中用作mps-1和tkk抑制剂的6-取代的咪唑并吡嗪
EP2651948A1 (en) 2010-12-17 2013-10-23 Bayer Intellectual Property GmbH Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
US20140135319A1 (en) * 2010-12-17 2014-05-15 Bayer Intellectual Property Gmbh 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
US20140038953A1 (en) 2011-01-21 2014-02-06 The General Hospital Corporation Compositions and methods for cardiovascular disease
EP2694500B1 (en) 2011-04-06 2015-05-27 Bayer Pharma Aktiengesellschaft Substituted imidazopyridines and intermediates thereof
PL3409278T3 (pl) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
CA2852937A1 (en) 2011-10-20 2013-04-25 Glaxosmithkline Llc Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators
JP6377068B2 (ja) * 2012-11-16 2018-08-22 ユニバーシティ・ヘルス・ネットワーク ピラゾロピリミジン化合物

Also Published As

Publication number Publication date
US20240287077A1 (en) 2024-08-29
PT3068786T (pt) 2018-07-26
NZ707432A (en) 2020-01-31
SI3068786T1 (sl) 2018-09-28
US10570143B2 (en) 2020-02-25
US9657025B2 (en) 2017-05-23
EP3068786A1 (en) 2016-09-21
BR112016010080A8 (pt) 2020-04-14
US10106545B2 (en) 2018-10-23
US20170217966A1 (en) 2017-08-03
US20160137651A1 (en) 2016-05-19
TWI679201B (zh) 2019-12-11
PL3068786T3 (pl) 2018-10-31
ES2686097T3 (es) 2018-10-16
SG11201603102TA (en) 2016-05-30
CA2889919A1 (en) 2014-05-22
IL245187B (en) 2019-12-31
CN105793261A (zh) 2016-07-20
EP2920181A4 (en) 2016-07-27
EP2920181A1 (en) 2015-09-23
WO2015070349A1 (en) 2015-05-21
AU2013344716B2 (en) 2018-03-01
JP2015537008A (ja) 2015-12-24
CN105793261B (zh) 2018-11-30
US20190040074A1 (en) 2019-02-07
US20220204511A1 (en) 2022-06-30
DK3068786T3 (en) 2018-07-16
US20170320881A1 (en) 2017-11-09
US20210009595A1 (en) 2021-01-14
EP2920181B1 (en) 2019-01-09
US20150299203A1 (en) 2015-10-22
US10167289B2 (en) 2019-01-01
TW201605860A (zh) 2016-02-16
HRP20181041T1 (hr) 2018-09-21
AU2013344716A1 (en) 2015-05-14
JP6377068B2 (ja) 2018-08-22
BR112016010080B1 (pt) 2020-12-29
US9573954B2 (en) 2017-02-21
ME03093B (me) 2019-01-20
MX2016006336A (es) 2016-09-06
HUE039351T2 (hu) 2018-12-28
US20190322669A1 (en) 2019-10-24
EP3068786A4 (en) 2017-04-12
IL245187A0 (en) 2016-06-30
CY1120480T1 (el) 2019-07-10
WO2014075168A1 (en) 2014-05-22
EP3068786B1 (en) 2018-06-06
CA2889919C (en) 2021-08-17
LT3068786T (lt) 2018-08-27
RS57481B1 (sr) 2018-10-31

Similar Documents

Publication Publication Date Title
MX373713B (es) Compuestos pirazolopirimidina.
PH12020550552A1 (en) Inhibitors of hepatitis c virus
CA2875877C (en) Syk inhibitors
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
PH12015501996B1 (en) Heterocyclic compounds and uses thereof
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
RS54873B1 (sr) Policiklična-karbamoilpiridonska jedinjenja i njihova farmaceutska upotreba
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
MD20140072A2 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
EA201492023A1 (ru) Регуляторы пути комплемента и их применение
RS54730B1 (sr) Inhibitori beta sekretaze
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
EA201201377A1 (ru) Определенные аминопиридазины, композиции на их основе и способы их использования
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
RS54207B1 (en) CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS
IN2014MN02652A (es)
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201300862A1 (ru) Ингибирование il17 и ifn-гамма для лечения аутоиммунного воспаления
IN2015DN01119A (es)
MX2015003594A (es) Agente terapeutico o profilactico para sindrome de lisis tumoral.
EA201891804A1 (ru) Тетрациклиновые соединения
EA201500931A1 (ru) Производные пиридин-4-ила
MX2015013224A (es) Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.
UA113086C2 (xx) Піразольні сполуки як інгібітори sglt1

Legal Events

Date Code Title Description
FG Grant or registration